言語を選択
Spike protein
Spike protein 詳細
| 英語名 | Coronavirus spike glycoprotein | 市販薬剤の数 | 15 |
| 治験薬の数 | 91 | ターゲットの別称 | Spike glycoprotein，E2，Peplomer protein，S，SARS-CoV-2 S protein |
| 研究＆開発段階 | Approved | ||
| 英語名 | Coronavirus spike glycoprotein |
| ターゲットの別称 | Spike glycoprotein，E2，Peplomer protein，S，SARS-CoV-2 S protein |
| 市販薬剤の数 | 15 |
| 治験薬の数 | 91 |
| 研究＆開発段階 | Approved |
Spike protein 製品リスト
- 属性
Protein (110)Beads (2)Kits (3)Antibody (2)
- 製品ライブラリ
オンライン (117)
- 種
SARS-CoV-2 (76)SARS (2)HCoV-229E (2)HCoV-NL63 (1)HCoV-HKU1 (2)HCoV-OC43 (1)Bat coronavirus (7)Pangolin coronavirus (2)SARS-CoV GD01 (1)SARS-CoV BtKY72 (1)Rhinolophus affinis coronavirus isolate LYRa11 (1)MERS (2)Mouse (2)SARS coronavirus GD03T0013 (1)SARS coronavirus frankfult-1 (1)SARS coronavirus SZ1 (2)SARS coronavirus PC4-127 (1)SARS coronavirus PC4-137 (1)Bat SARS-like coronavirus WIV1 (1)SARS-CoV (1)SARS coronavirus GZ-C (1)SARS coronavirus Urbani (1)SARS coronavirus PC4-13 (1)SARS coronavirus Sino1-11 (1)Bat SARS-like coronavirus isolate Rs4084 (1)Bat SARS-like coronavirus isolate Rs7327 (1)Bat coronavirus BANAL20-236 (1)Bat coronavirus Anlong103 (1)Bat coronavirus RS4081 (1)
- タグ
His Tag & Avi Tag (23)His Tag (87)- (7)
- マーカー
Biotin-labeled (23)Unconjugated (89)- (5)
総数量117
- 1
- 2
- 3
- 4
- 5
- 6
- 12
Spike proteinバックグランド
It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Spike protein分子の別称
Spike,S protein,Spike glycoprotein,S glycoprotein
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| VLPCOV-05 | VLPCOV-05 | Phase 3 Clinical | Vlp Therapeutics | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| VLPCOV-04 | VLPCOV-04 | Phase 3 Clinical | Vlp Therapeutics | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Bamlanivimab | LY-3819253 | Phase 3 Clinical | AbCellera Biologics Inc, Eli Lilly And Company | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | 詳細 |
| mRNA-1273.231 | mRNA-1273.231 | Phase 3 Clinical | Moderna Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| mRNA-1273.815 | mRNA-1273.815 | Phase 3 Clinical | Moderna Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Riltozinameran | Phase 3 Clinical | Biontech Se, Pfizer Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| YKYY-017 | YKYY-017 | Phase 3 Clinical | Youcare Pharmaceutical Group Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| AZD-5156 | AZD-5156; Cilgavimab/AZD 3152 | Phase 3 Clinical | Astrazeneca Plc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| abdavomeran | BNT162b1 | Phase 3 Clinical | Biontech Se | Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Respiratory Tract Infections; RNA Virus Infections; Virus Diseases | 詳細 |
| Recombinant SARS-CoV-2 tetravalent(Alpha/Beta variant) S-trimer protein vaccine (SinoCelltech) | SCTV-01-E | Phase 3 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| GSK-4362620A | GSK-4362620A | Phase 3 Clinical | Gsk Vaccines Gmbh, Medicago Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Recombinant SARS-CoV-2 bivalent (Alpha/Beta variant) S-trimer protein vaccine (SinoCelltech) | SCTV-01-C | Phase 3 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Ogalvibart/Crexavibart | BMS-986414/C 144LS; C 144LS/BMS-986414; BMS-986414 + BMS-986413; C 144LS/IM051; C 144LS/ogalvibart; C-135-LS/C-144-LS; C-144-LS/C-135-LS; IM051/C 144LS | Phase 3 Clinical | Bristol Myers Squibb Srlcompany, The Rockefeller University | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | 詳細 |
| Imdevimab | RG-6412 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| ABP-300 | ABP-300; MW-05(Mabwell/Abpro) | Phase 3 Clinical | Abpro Corp, Mabwell (Shanghai) Bioscience Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Ensovibep | MP-0420 | Phase 3 Clinical | Molecular Partners Ag | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Upanovimab | HB-27; SCTA-01 | Phase 3 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| STI-2099 | STI-2099 | Phase 2 Clinical | Sorrento Therapeutics Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| BNT162a1 | Phase 2 Clinical | Biontech Se | Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Respiratory Tract Infections; RNA Virus Infections; Virus Diseases | 詳細 | |
| Pidacmeran | BNT162c2 | Phase 2 Clinical | Biontech Se | Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Respiratory Tract Infections; RNA Virus Infections; Virus Diseases | 詳細 |
| Recombinant SARS-CoV-2 Beta/Omicron (BA.1/BQ.1.1/XBB.1) S-trimer protein vaccine (SinoCelltech) | SCTV01E-2 | Phase 2 Clinical | SinoCelltech Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| SA-55 | SA55; SA-55; BD55-5514 | Phase 2 Clinical | Sinovac Biotech Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Reluscovtogene ralaplasmid | INO-4800; INO4800; PGX-9501 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Hepatitis B, Chronic | 詳細 |
| BM-219 | BM-219; BM219 | Phase 2 Clinical | Suzhou Biomissile Pharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| SARS-CoV-2 mRNA Vaccine(Argorna) | RBMRNA-176 | Phase 2 Clinical | Argorna Pharmaceuticals Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Recombinant SARS-CoV-2 Vaccine（variant）（Shanghai Zerun） | Phase 2 Clinical | Shanghai Zerun Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| COVID-19 mRNA Vaccine(Cnbg-Virogin) | ZSVG-02-O | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| FBR-002 | FBR-002 | Phase 2 Clinical | Fabentech | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| IBIO123 | IBIO-123 | Phase 2 Clinical | Immune Biosolutions Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Bebtelovimab | LY-CoV1404 monoclonal antibody; LY-3853113; LY-CoV 1404 mAb; LY-CoV1404 | Phase 2 Clinical | Eli Lilly And Company | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| ChAd-triCoV | ChAd-triCoV; ChAd-triCoV/Mac | Phase 2 Clinical | Canadian Institutes Of Health Research (Cihr), Mcmaster University | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Casirivimab | RG-6413 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| LY-CovMab | LY-CovMab | Phase 2 Clinical | Luye Pharma Group Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| COR-101 | STE90-C11 | Phase 2 Clinical | Corat Therapeutics Gmbh | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| GLS-5310 | GLS-5310 | Phase 2 Clinical | Geneone Life Science Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| BGB-DXP604 | DXP-604; BGB-DXP604 | Phase 2 Clinical | Singlomics Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Lomtegovimab | BI-767551 | Phase 2 Clinical | German Center For Infection Research, University Of Cologne | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Equine immunoglobulin anti SARS-CoV-2 (Caja Costarricense de Seguro Social) | Phase 2 Clinical | Universidad De Costa Rica | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| ChulaCov19 mRNA vaccine | Phase 2 Clinical | Chulalongkorn University | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| DXP-593 | BGB DXP593; DXP-593 | Phase 2 Clinical | Singlomics Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Etesevimab | LY-CoV016; LY-CoV-016; JS-016; LY-3832479 | Phase 2 Clinical | Institute Of Microbiology Of Chinese Academy Of Sciences, Shanghai Junshi Biosciences Co Ltd | Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome | 詳細 |
| NeomiVac | Phase 1 Clinical | Neovacs | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| AT-301 (Atossa Therapeutics) | AT-301A; AT-301B | Phase 1 Clinical | Atossa Therapeutics Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| recombinant SARS-CoV-2 S-trimer vaccine (Binhui Biopharmaceutical) | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| DNA-based mAbs (Inovio/AstraZeneca/Wistar Institute/University of Pennsylvania/Indiana University) | dMAb-1; dMAb; dMAb-2 | Phase 1 Clinical | Inovio Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| SARS-CoV-2 vaccine (The Scientific and Technological Research Council of Turkey) | Phase 1 Clinical | The Scientific And Technological Research Council Of Turkey | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| SARS-CoV-2 specific cytotoxic T lymphocytes (M.D. Anderson Cancer Center) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Coronavirus Disease 2019 (COVID-19); Pneumonia, Viral; Respiratory Distress Syndrome, Adult | 詳細 | |
| RBD protein vaccine | Phase 1 Clinical | Copyright The Peter Doherty Institute For Infection And Immunity | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| SPK-002 | SPK-002 | Phase 1 Clinical | Instituto Pasteur | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Hexapro-based SARS-CoV-2 vaccine (Vaxxas/University of Queensland) | Phase 1 Clinical | The University Of Queensland | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| COVID-19 vacine targeting SARS-CoV-2 spike protein RBD (Monash Institute of Pharmaceutical Sciences/Burnet Institute) | Phase 1 Clinical | Monash Institute of Pharmaceutical Sciences | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| COReNAPCIN | Phase 1 Clinical | Renap Industrial Group | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| AVACC-10 | AVACC-10 | Phase 1 Clinical | Intravacc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| LMN-301 | LMN301 | Phase 1 Clinical | Lumen Bioscience Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| BAT-2022 | BAT-2022 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| CV-2-CoV | CV-2-CoV | Phase 1 Clinical | Curevac Ag, Glaxosmithkline Spa | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| SCB-2020S | SCB-2020S | Phase 1 Clinical | Clover Biopharmaceuticals Aus Pty Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| IN-006 | IN-006 | Phase 1 Clinical | Inhalon Biopharma Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| SW-0123 | SW-0123; DF-104B1 | Phase 1 Clinical | Stemirna Therapeutics | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| PDI-204 | PDI-204; PDI204 | Phase 1 Clinical | University Of Melbourne | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Regdanvimab/CT-P63 | Phase 1 Clinical | Celltrion Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| AER-001 (Aerium Therapeutics) | AER-001 | Phase 1 Clinical | Centre Hospitalier Universitaire Vaudois, Swiss Federal Institute Of Technology | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| ABBV-2B04 | ABBV-2B04 | Phase 1 Clinical | Abbvie Inc, Washington University | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| RBMRNA-405 | RBMRNA-405 | Phase 1 Clinical | Argorna Pharmaceuticals Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| GB-0669 | GB-0669 | Phase 1 Clinical | Generate Biomedicines Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| PA-001 (PeptiDream) | PA-001 | Phase 1 Clinical | PeptiDream Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| REGN17092 | REGN-17092; REGN17092 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | 詳細 | |
| B/HPIV3/S-6P | B/HPIV-3/S-6-P | Phase 1 Clinical | National Institutes Of Health | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| F-61 | F-61 | Phase 1 Clinical | Wuhan Institute Of Biological Products Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| GRT-R-918 | GRT-R918; GRT-R-918 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| GRT-R-914 | GRT-R914; GRT-R-914 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| GRT-R-912 | GRT-R912; GRT-R-912 | Phase 1 Clinical | Gritstone Bio Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| MTx-COVAB36 | MTx-COVAB36 | Phase 1 Clinical | Memo Therapeutics AG | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Gorivitug | REGN-15160 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | 詳細 | |
| SI-F019 | SI-F019; F-019; SZ-F019 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | 詳細 | |
| CT-P63 | CT-P-63; CT-P63 | Phase 1 Clinical | Celltrion Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| JS-026 | JS-026 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Ad5-triCoV/Mac | Ad5-triCoV/Mac | Phase 1 Clinical | Canadian Institutes Of Health Research (Cihr), Mcmaster University | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| JMB-2002 | JMB-2002 | Phase 1 Clinical | Jiangxi Jemincare Group Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Simaravibart | MAD-0004J08 | Phase 1 Clinical | Fondazione Toscana Life Sciences | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Ogalvibart | BMS-986414 | Phase 1 Clinical | Bristol Myers Squibb Srlcompany, The Rockefeller University | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Crexavibart | C144-LS; C144LS; BMS-986413 | Phase 1 Clinical | Bristol Myers Squibb Srlcompany, The Rockefeller University | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| ABBV-47D11 | HBM9022; ABBV-47D11; HBM-9022; 47D11 | Phase 1 Clinical | Abbvie Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Enuzovimab | HFB-3013; HFB30132A | Phase 1 Clinical | HiFiBiO Therapeutics | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| ADM-03820 | Phase 1 Clinical | Ology Bioservices Inc | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| HLX-71 | HLX-71 | Phase 1 Clinical | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| SARS-COV2 vaccine (DreamTec Research) | Clinical | DreamTec Research Ltd | Coronavirus Disease 2019 (COVID-19); Pneumonia | 詳細 | |
| Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) | Clinical | Anhui Zhifei Longcom Biopharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| SA-58 | SA-58 | Clinical | Sinovac Life Sciences Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| AAHI-SC2 | AAHI-SC2 | Immunitybio Inc | 詳細 | ||
| HY-3000 | HY-3000 | Hybio Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Tozinameran | BNT162b2; PF-07302048; BNT-161b1; BNT162; Bnt-162b2; BNT162b2SA; BNT-162b5 | Approved | Biontech Se, Pfizer Inc | 复必泰, 復必泰, Comirnaty | United Kingdom | Coronavirus Disease 2019 (COVID-19) | Biontech Se | 2020-12-02 | Anaphylaxis; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Drug-Related Side Effects and Adverse Reactions; Infections; Influenza, Human; Neoplasms; Respiratory Tract Infections; RNA Virus Infections; Severe Acute Respiratory Syndrome; Virus Diseases | 詳細 |
| Recombinant novel coronavirus vaccine (adenovirus type 5 vector) (CanSinoBio) | Approved | Chinese Academy Of Military Medical Sciences, Tianjin Cansino Biotechnology Inc | 克威莎, Convidecia, Convidecia Air | Mainland China | Coronavirus Disease 2019 (COVID-19) | Tianjin Cansino Biotechnology Inc | 2021-02-25 | Coronavirus Disease 2019 (COVID-19) | 詳細 | |
| Tozinameran/famtozinameran | Approved | BioNTech Manufacturing GmbH | Canada | Coronavirus Disease 2019 (COVID-19) | BioNTech Manufacturing GmbH | 2022-10-11 | Coronavirus Disease 2019 (COVID-19) | 詳細 | ||
| Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 Cell)(Chengdu WestVac) | WSK-V102C | Approved | Chengdu WestVac Biopharma Co Ltd, West China Hospital Of Sichuan University | 威克欣®3价XBB疫苗 | Mainland China | Coronavirus Disease 2019 (COVID-19) | West China Hospital Of Sichuan University, Chengdu WestVac Biopharma Co Ltd | 2023-06-08 | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Recombinant COVID-19 Protein Vaccine (Sf9 Cell) (Chengdu WestVac) | WSK-V101 | Approved | Chengdu WestVac Biopharma Co Ltd | 威克欣 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Chengdu WestVac Biopharma Co Ltd, West China Hospital Of Sichuan University | 2022-12-05 | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Gam-COVID-Vac | Approved | Gamaleya Research Institute Of Epidemiology And Microbiology, Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation | Sputnik V | Russian Federation | Coronavirus Disease 2019 (COVID-19) | Gamaleya Research Institute Of Epidemiology And Microbiology | 2020-08-11 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | 詳細 | |
| Sipavibart | AZD3152; AZD-3152 | Approved | RQ Biotechnology Ltd | Kavigale | Japan | Coronavirus Disease 2019 (COVID-19) | Astrazeneca Kk | 2024-12-27 | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Pemivibart | VYD-222 | Approved | Invivyd Inc | PEMGARDA, Pemgarda | United States | Coronavirus Disease 2019 (COVID-19) | Invivyd Inc | 2025-03-05 | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Casirivimab/imdevimab | REGN-10933+REGN-10987; RG-6413+RG6412; REGEN-COV-2; REGN-COV2; REGN-COV-2; REGEN-COV | Approved | F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc | ロナプリーブ, REGEN-COV, RONAPREVE | Japan | Coronavirus Disease 2019 (COVID-19) | Chugai Pharmaceutical Co Ltd | 2021-07-19 | Chronic Disease; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Rejection of organ transplantation | 詳細 |
| Tixagevimab/Cilgavimab | AZD-7442; AZD7442 | Approved | Vanderbilt University Medical Center | Evusheld, 恩适得 | United Kingdom | Coronavirus Disease 2019 (COVID-19) | Astrazeneca Uk Ltd | 2022-03-16 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Leukemia, Lymphocytic, Chronic, B-Cell | 詳細 |
| Sotrovimab | VIR-7831; GSK-4182136 | Approved | Vir Biotechnology Inc | Xevudy | Australia | Coronavirus Disease 2019 (COVID-19) | Vir Biotechnology Inc | 2021-08-23 | Coronavirus Disease 2019 (COVID-19); Hematologic Neoplasms; Lymphoma; Solid tumours | 詳細 |
| Regdanvimab | CT-P59 | Approved | Celltrion Inc | Regkirona | South Korea | Coronavirus Disease 2019 (COVID-19) | Celltrion Inc | 2021-09-18 | Coronavirus Disease 2019 (COVID-19) | 詳細 |
| Amubarvimab | BRII-196; BRII196 | Approved | Brii Biosciences (Beijing) Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Brii Biosciences (Shanghai) Co Ltd | 2021-12-08 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | 詳細 | |
| Romlusevimab | BRII198; BRII-198 | Approved | Brii Biosciences (Beijing) Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Brii Biosciences (Shanghai) Co Ltd | 2021-12-08 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | 詳細 | |
| Recombinant SARS-CoV-2 vaccine (CHO Cell) (Zhifei Longcom Biopharmaceutical) | ZF2001 | Approved | Anhui Zhifei Longcom Biopharmaceutical Co Ltd, Institute Of Microbiology Of Chinese Academy Of Sciences | 智克威得 | Uzbekistan | Coronavirus Disease 2019 (COVID-19) | Anhui Zhifei Longcom Biopharmaceutical Co Ltd | 2021-03-01 | Coronavirus Disease 2019 (COVID-19); Coronavirus Infections | 詳細 |
レビュー
M***s2025-02-07
2評価We ordered this peptide to use with klickmers from Immudex to look at immune response to COVID in cancer patients. We were very satisfied with the specific staining we achieved and the excellent customer service received. The product was straightforward to reconstitute and arrived very quickly (UK). The QR code with the vial allows quick access to the CoA and useful information about the product.- M***g2022-05-07 0評価This product was purchased to conduct plasma screens for anti-SARS-CoV-2 antibodies and perform antibody monoclonal antibody binding/capture studies on BLI. This product came out in a timely manner following its designation as a VOC and was delivered quickly. The protein produced high quality and consistent results in both MSD and BLI experiments and is remarkably stable at 4C where it was stored for approximately 3 weeks without any appreciable change in experimental result.
- A***r2021-09-28 0評価We bought an array or anti bodies and associated proteins to do testing for pull down and binding efficiency in a couple different assays. Then compared with our technology for binding comparisons. The proteins and anti bodies were relatively high in concentration and worked well for the experiments where the results were consistent and reproducible (which was the entire hope for the experiment from the start.) Working with ACRO is very easy and we will be ordering from them more in the future
詳しく読む
- 詳細
- 製品リスト
- 市販薬剤に関する情報
- レビュー
- 治験薬に関する情報
共有：
メッセージ
お問い合わせ
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8